IDEAYA Biosciences (IDYA) EBT (2018 - 2026)

IDEAYA Biosciences has reported EBT for 9 years, with the latest figure at -$232.8 million in Q1 2026.

• Quarterly EBT fell 149.92% year-over-year to -$232.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$432.1 million (up 19.4% YoY) and the FY2025 annual result came in at -$354.3 million, up 27.94% from the prior year.
• EBT slipped to -$232.8 million in Q1 2026 per IDYA's latest filing, from -$94.1 million in the prior quarter.
• Over five years, EBT peaked at $30.2 million in Q3 2025 and troughed at -$232.8 million in Q1 2026.
• A 5-year average of -$74.2 million and a median of -$39.2 million in 2023 frame the typical range for EBT.
• The sharpest annual moves came in 2024 and 2025: EBT plunged 379.35% in 2024, then soared 122.45% in 2025.
• Over 5 years, EBT stood at -$25.3 million in 2022, then tumbled by 54.68% to -$39.2 million in 2023, then tumbled by 275.66% to -$147.2 million in 2024, then surged by 36.09% to -$94.1 million in 2025, then sank by 147.48% to -$232.8 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$232.8 million, -$94.1 million, and $30.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.